Liersch T, Langer C, Jakob C, Müller D, Ghadimi B M, Siemer A, Markus P M, Füzesi L, Becker H
Klinik und Poliklinik für Allgemeinchirurgie, Universitätsklinikum der Georg-August-Universität Göttingen.
Chirurg. 2003 Mar;74(3):224-34. doi: 10.1007/s00104-002-0609-z.
Neoadjuvant radiochemotherapy (neoRT/CT) in locally advanced rectal cancer requires an exact initial determination of the depth of the cancerous infiltration (T-status) and of locoregional lymph node metastasis (N-status). For staging and restaging, contrast-enhanced computed tomography (CT) is usually used. In specialised centers, the endorectal ultrasound (rES) may be preferred.
Between January 1998 and May 2001, the T- and N-status of 102 patients with adenocarcinoma of the rectum (> or =T3 or N+) was determined prospectively by rES and CT (group I: n=61 without neo-RT/CT, examined once; group II: n=41 examined before and after neoRT/CT). All diagnostic findings were compared using the (y)pTNM-classification.
In the patients from group I, the depth of infiltration (uT) was predicted correctly by rES in 75% and by CT in 48% of cases; the carcinomas were understaged in 10% and 41% of cases and overstaged in 15% and 11%, respectively. According to the histopathological findings, the N-status was determined correctly by rES and CT in 75% and 57% of cases, understaging occurred in 8% and 30% and overstaging in 17% and 13%, respectively. In cases in which both methods resulted in identical T- (uT+ctT) or N-staging (uN+ctN), the accuracy increased to 82% and 80%, respectively. In patients from group II, after neoRT/CT rES and CT allowed the exact prediction of the yuT-stage in 66% and 51%, respectively. Only 2% were understaged by rES (understaging by CT: 22%). Overstaging occurred in 32% and 27% by rES and CT, respectively. The N-status determined by rES and CT was in accordance with the histopathological findings in 68% and 76%of cases, respectively. Understaging occurred in 20% and 17%,overstaging in 12% and 7%, respectively. Again identical staging results in both rES and CT increased the accuracy of the T- (yuT+yctT) or N- (yuN+yctN) classification to 90% and 83%, respectively. In group II, downsizing of the tumor by more than one T-stage was correctly assessed by rES results in 15/20 cases (75%). A complete remission of initial uT3-carcinoma was diagnosed correctly in only two of eight ypT0-cases. In contrast, CT demonstrated a remission of disease in all cases but was unable to predict the extent of tumour reduction. A remission of lymph node metastasis was accurately shown by rES in 17/19 cases (90%) and by CT in 10/12 cases (83%).
The staging of pretherapeutic, locoregional T- and N-status by rES is superior to that by CT (T-status: P=0.0164, N-status: P=0.0035). At restaging, rES offers higher accuracy in the detection of residual tumour infiltration (but not significantly to CT, yT-status: P=0.0833, yN-status: P=0.7962) and assessment of local remission. Therefore rES should be the method of choice in staging to avoid overtreatment in neoadjuvant settings.After neoRT/CT, the predictive efficacy of the rES for the downsizing/-staging of rectal cancer must be evaluated on greater numbers of patients receiving standardised diagnostic procedures and therapy.
局部晚期直肠癌的新辅助放化疗(neoRT/CT)需要准确初步确定癌浸润深度(T分期)和局部区域淋巴结转移情况(N分期)。对于分期及再分期,通常使用增强计算机断层扫描(CT)。在专业中心,直肠内超声(rES)可能更受青睐。
1998年1月至2001年5月,前瞻性地通过rES和CT确定102例直肠腺癌患者(≥T3或N+)的T和N分期(I组:n = 61,未接受新辅助RT/CT,检查一次;II组:n = 41,在新辅助RT/CT前后检查)。所有诊断结果使用(y)pTNM分类进行比较。
在I组患者中,rES正确预测浸润深度(uT)的病例占75%,CT为48%;癌分期过低的病例分别占10%和41%,分期过高的病例分别占15%和11%。根据组织病理学结果,rES和CT正确确定N分期的病例分别占75%和57%,分期过低分别占8%和30%,分期过高分别占17%和13%。两种方法得出相同的T分期(uT+ctT)或N分期(uN+ctN)时,准确率分别提高到82%和80%。在II组患者中,新辅助RT/CT后,rES和CT分别在66%和51%的病例中准确预测了yuT分期。rES分期过低的仅2%(CT为22%)。rES和CT分期过高的分别为32%和27%。rES和CT确定的N分期分别在68%和76%的病例中与组织病理学结果一致。分期过低分别占20%和17%,分期过高分别占12%和7%。同样,rES和CT得出相同分期结果时,T分期(yuT+yctT)或N分期(yuN+yctN)的准确率分别提高到90%和83%。在II组中,rES结果正确评估了20例中15例(75%)肿瘤缩小超过一个T分期的情况。8例ypT0病例中仅2例正确诊断出初始uT3癌完全缓解。相比之下,CT显示所有病例疾病缓解,但无法预测肿瘤缩小程度。rES在19例中的17例(90%)和CT在12例中的10例(83%)准确显示了淋巴结转移缓解情况。
rES对治疗前局部区域T和N分期的准确性优于CT(T分期:P = 0.0164,N分期:P = 0.0035)。再分期时,rES在检测残留肿瘤浸润方面具有更高准确性(但与CT相比无显著差异,yT分期:P = 0.0833,yN分期:P = 0.7962)以及评估局部缓解情况。因此,rES应作为分期的首选方法,以避免新辅助治疗中的过度治疗。新辅助RT/CT后,rES对直肠癌缩小/分期的预测效果必须在更多接受标准化诊断程序和治疗的患者中进行评估。